Profiling and hormonal therapy for acne in women

Indian Journal of Dermatology

Volumn 59, Issue 2, 2014, Pages 107-115

  Ghosh, Sangita ^a   Chaudhuri, Soumik ^a   Jain, Vijay ^a   Aggarwal, Kamal ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acne; hormonal therapy; hyperandrogenism

Indexed keywords

BUSERELIN; CYPROTERONE ACETATE; DESOGESTREL PLUS ESTRADIOL; DOXYCYCLINE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; FEMILON; FINASTERIDE; FLUTAMIDE; KETOCONAZOLE; LEUPRORELIN; METFORMIN; SPIRONOLACTONE; TETRACYCLINE; UNCLASSIFIED DRUG;

ACNE VULGARIS; ARTICLE; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; MONOTHERAPY; PATHOGENESIS; PATIENT SELECTION; PRESCRIPTION; PROPIONIBACTERIUM ACNES; SEBUM SECRETION; THERAPY;

EID: 84896822085     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.127667     Document Type: Article

References (67)

1. Cunliffe WJ, Gollnick HP. Acne: Diagnosis and management. London: Martin Dunitz; 2001. p. 49-103.
2. Simpson NB, Cunliffe WJ. Disorders of the sebaceous glands. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Text book of Dermatology. 7 th ed. USA: Blackwell Science; 2004. p. 43.1-43.75.
3. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008;27:188-96.
4. Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol 2009;8:615-8.
5. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49:S1-38.
6. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med 2000;9:179-87.
7. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: A review of clinical features. Br J Dermatol 1997;136:66-70.
8. Shaw JC. Low-dose adjunctive spiranolactone in the treatment of acne in a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000;43:498-502.
9. Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995;32:15-25.
10. Pochi, PE: Hormones and acne. Semin Dermatol 1982;1:265.
11. Pochi PE. The pathogenesis and treatment of acne. Ann Rev Med 1990;41:187-98.
12. Pochi PE. Hormonal aspects of acne. J Int Postgrad Med 1991;4:7-10.
13. Harper JC. Antiandrogen therapy for skin disease and hair disease. Dermatol Clin 2006;24:137-43.
14. K Eric, A Ricardo: Ovarian hormones and andrenal androgens during a women's life span. J Am Acad Dermatol 2001;45:S105-15.
15. Rittmaster RS. Hirsutism [review]. Lancet 1997;349:191-5.
16. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005;353:2578-88.
17. Collu R, Ducharme R. Role of adrenal steroids in the initiation of pubertal mechanisms. In: James VHT, Serio M, Giusti G, Martini L, editors. The endocrine function of the human adrenal cortex. Proceedings of the Serono Symposia. Vol. 18. New York: Academic Press; 1978. p. 547-59.
18. Shuster S, Thody AJ. The control and measurement of sebum secretion. J Invest Dermatol 1974;62:172-90.
19. Klingman AM, Shelly WB. An investigation of the biology of the human sebaceous gland. J Invest Dermatol. 1958;30:99-125.
20. Pochi PE, Strauss JS, Sebaceous gland suppression with ethinyl oestradiol and diethyl stilboestrol. Arch Dermatol 1973;108:210-1.
21. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrin Rev 1995;16:322-53.
22. Chen W, Thibout D, Zouboulis CC. cutaneous androgen metabolism: Basic research and clinical perspective. J Invest Dermatol 2002;119:992-1007.
23. Schmidt JB, Lindmaier A, Spona J. Hyperprolactinemia and hypophyseal hypothyroidism as cofactors in hirsutism and androgen-induced alopecia in women. Hautarzt 1991;42:168-72.
24. Beylot C, Doutre MS, Beylot-Berry M. Oral Contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998;196:148-52.
25. De Raeve L, De Schepper J, Smitz J. Prepubertal acne. A cutaneous marker of androgen excess. J Am Acad Dermatol 1996;34:187-95.
26. Yen S, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435-42.
27. Junkins-Hopkins JM. Hormone therapy for acne. J Am Acad Dermatol 2010;62:486-8.
28. Lucky AW, McGuire J, Rosenfield RL, Lucky PA, Rich BH. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983;81:70-4.
29. Darley CR, Kirby JD, Besser GM, Munro DD, Edwards CR, Rees LH. Circulating testosterone, sex hormone binding globulin and prolactin in women with late onset or persistent acne vulgaris. Br J Dermatol 1982;106:517-22.
30. Cibula D, Hill M, Vohradnikova O, Kuzel D, Fanta M, Zivny J. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000;143:399-404.
31. Kubba R, Bajaj AK, Thappa DM, Sharma R, Vedamurthy M, Dhar S, et al. Acne in India: guidelines for management-IAA consensus document. Indian J Dermatol Venereol Leprol 2009;75 Suppl 1:1-62.
32. Rotterdam ESHRE\ASRM sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risk related to polycystic ovary syndrome. Hum Reprod 2004;19:41-7.
33. Belan AH, Laven JS, Tan SL, Dewally D. Ultrasound assessment of the polycystic ovary: International consensus definition. Hum Reprod Update 2003;9:505-14.
34. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988;50:197-212.
35. Cara JF, Fan J, Azzarello J, Rosenfield RL. Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 1990;86:560-5.
36. Rosenfield RL. Current concepts of polycystic ovary syndrome. Baillière's Clin Obstet Gynaecol 1997;11:307-33.
37. Lin-Su K, Nimkarn S, New MI. Congenital adrenal hyperplasia in adolescents: Diagnosis and management. Ann N Y Acad Sci 2008;1135:95-8.
38. Chang RJ, Katz SE. Diagnosis of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:397-408.
39. Thiboutot D. Endocrinilogical evaluation and hormonal therapy for difficult acne. J Eur Acad Dermatol Venereol 2001;15:57-61.
40. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009;3:CD004425.
41. Lucky A, Henderson T, Olson W, Robisch DM, Lebwohl M, Swinger LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
42. Rothman KF, Lucky AW. Acne vulgaris. Adv Dermatol 1993;8:347-75.
43. Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. Arch and Diane Berson. J Clin Aesthet Dermatol 2009;2:16-22.
44. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: A pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011;155:171-5.
45. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008;27:188-96.
46. Harper JC. Should dermatologists prescribe hormonal contraceptives for acne? Dermatol Ther 2009;22:452-7.
47. Neely JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 1991;77: 416-20.
48. Murphy AA, Zacur HA, Charache P, Burkman RT. The effect of tetracycline on levels of oral contraceptives. Am J Obstet Gynecol 1991;164:28-33.
49. Haroun M. Hormonal therapy of acne. J Cutan Med Surg 2004;8(Suppl 4):6-10.
50. Van Wayjen R, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: Efficacy, metabolic, and endocrine effects. Exp Clin Endocrinol Diabetes 1995;103:241-51.
51. Gollnick H, Albring M, Brill K. Efficacite de l'acetate de cyproterone oral associe a l'ethinylestradiol dans le traitement de l'acne tardive de type facial. Ann Endocrinol 1999;60:157-66.
52. Hammerstein J, Meckies J, Leo-Rossberg, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism, and virilism. J Steroid Biochem 1975;6:827-36.
53. Faloia E, Filipponi S, Mancini V, Morosini P, De Pirro R. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J Endocrinol Invest 1993;16:675.
54. Cipolla L, Zagni R, Ferrante B, Giannetta G, Soliani A. Treatment with GnRH analogs in polycystic ovarian disease. A collaborative multicenter study. The preliminary results. Minerva Ginecol 1994;46:85-9.
55. Lucky A. Hormonal correlates of acne and hirsutism. Am J Med1995;98:89S-94S.
56. Goodfellow A, Alaghband-Zadeh J, Carter G, Cream JJ, Holland S, Scully J, et al. Oral spiranolactone improves acne vulgaris and reduces sebum secretion. Br J Dermatol 1984;111:209-14.
57. Adalatkhah H, Pourfarzi F, Sadeghi-Bazargani H. Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: A pilot randomized clinical trial. Clin Cosmet Investig Dermatol 2011;4:117-21.
58. Wysowski D, Freiman J, Tourtelot J, Horton M. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993;118:860-4.
59. Sawaya ME. Antiandrogens and androgen inhibitors. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy, 2 nd ed. New York: Saunders; 2007. p. 429-30.
60. Venturoli S, Fabbri R, Dal Prato L, Mantovani B, Capelli M, Magrini O, et al. Ketoconazole therapy for women with acne and/or hirsutism. J Clin Endocrinol Metab 1990;71:335-9.
61. Martikainen H, Heikkinen J, Ruokonen A, Kauppila A. Hormonal and clinical effects of ketoconazole in hirsute women. J Clin Endocrinol Metab 1988;66:987-91.
62. Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol 2007;23:142-5.
63. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome Gynecol Endocrinol 2003;17:51-6.
64. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database System Rev 2007;1:CD005552.
65. Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12:243-52.
66. Loose DS, Stancel GM. Estrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11 th ed. New York: McGraw-Hill Company; 2006. p. 1565-7.
67. Davis SN. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11 th ed. New York: McGraw-Hill Company; 2006. p. 1638-9.